Information Provided By: 
Fly News Breaks for August 11, 2017
TXMD
Aug 11, 2017 | 06:11 EDT
Deutsche Bank analyst Esther Rajavelu views TherapeuticsMD's announcement that the FDA will review in detail, as part of the data package for TX-004, a large NIH-sponsored observational study on long-term, real world use of vaginal estrogens as a "small positive." While the analyst remains cautious on the timing and outcome of the review, she sees the news as an "incremental step in the right direction." Rajavelu continues to model for a TX-004 launch in 2019. The analyst keeps a Buy rating on TherapeuticsMD with a $10 price target.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
